ResearcherShanghai Jiao Tong UniversityActive in the last 2 years

Long Jiang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-3230-4522; OpenAlex author ID A5036814437. Sources: ClinicalTrials.gov.

Their work

Papers: 1
Trials: 1 (principal investigator on 1)
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2023: 1 trial · 2024: none · 2025: 1 paper

Papers 1

Utidelone suppresses PDAC growth and enhances gemcitabine therapy by inducing immunogenic cell death. Co-author DOI 10.1016/j.isci.2025.112509 ↗

Trials 1

Clinical Study of Multimodal Ablation Remodeling Immunosensitized PD-1 in the Treatment of Pancreatic Cancer With Liver Metastasis Principal investigator NCT06307080 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Haitao Gu · 1 shared paper, 2025 · strength 0.25
- Paper Utidelone suppresses PDAC growth and enhances gemcitabine therapy by inducing immunogenic cell death. DOI 10.1016/j.isci.2025.112509 ↗
Qi Li · 1 shared paper, 2025 · strength 0.25
- Paper Utidelone suppresses PDAC growth and enhances gemcitabine therapy by inducing immunogenic cell death. DOI 10.1016/j.isci.2025.112509 ↗
Jingyi Zhou · 1 shared paper, 2025 · strength 0.25
- Paper Utidelone suppresses PDAC growth and enhances gemcitabine therapy by inducing immunogenic cell death. DOI 10.1016/j.isci.2025.112509 ↗
Chuan Liu · 1 shared paper, 2025 · strength 0.25
- Paper Utidelone suppresses PDAC growth and enhances gemcitabine therapy by inducing immunogenic cell death. DOI 10.1016/j.isci.2025.112509 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.